The Russian government may expand the list of purchased high-priced drugs for its needs by beginning purchases of risdiplam – a drug for treatment of spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent
Several days ago the Commission on the Formation of Lists of Drugs of the Russian Ministry of Health recommended the national government to include a second drug for the treatment of SMA, Evrysdi (risdiplam) which is produced by Swiss pharma giant Roche (ROG: SIX), in the list of essential and vital drugs in the Russian market.
According to some local analysts, the inclusion of risdiplam in the list of essential drugs will help adult patients with SMA to a greater extent, as for the majority of them procurements of the drug, so far, have been carried from regional budgets, which funding has significantly declined in recent months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze